Clinical characterization of unknown/cryptogenic status epilepticus suspected as encephalitis: A multicenter cohort study
- Authors
- Shin, Jung-Won; Koo, Yong Seo; Kim, Young-Soo; Kim, Dong Wook; Kim, Kwang Ki; Lee, Seo-Young; Kim, Hyun Kyung; Moon, Hye-Jin; Lim, Jung-Ah; Byun, Jung-Ick; Sunwoo, Jun-Sang; Moon, Jangsup; Lee, Soon-Tae; Jung, Keun-Hwa; Park, Kyung-Il; Chu, Kon; Kim, Jae Moon; Cho, Yong-Won; Jung, Ki-Young; Lee, Sang Kun
- Issue Date
- 15-Feb-2018
- Publisher
- ELSEVIER SCIENCE BV
- Keywords
- Status epilepticus; Inflammatory CNS disease; Autoimmune encephalitis; Immunotherapy; Unknown/cryptogenic
- Citation
- JOURNAL OF NEUROIMMUNOLOGY, v.315, pp 1 - 8
- Pages
- 8
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- JOURNAL OF NEUROIMMUNOLOGY
- Volume
- 315
- Start Page
- 1
- End Page
- 8
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/34117
- DOI
- 10.1016/j.jneuroim.2017.12.004
- ISSN
- 0165-5728
1872-8421
- Abstract
- Autoimmune and unknown/cryptogenic encephalitis have been increasingly noted in the inflammatory etiology of new-onset status epilepticus (SE). We aimed to investigate clinical characteristics and the potential role of immunotherapy in encephalitis-related adult SE through our multicenter prospective SE registry. Among the 274 patients with SE, 35 (12.8%) patients demonstrated an inflammatory etiology and 19 out of 35 (54.3%) patients demonstrated unknown/cryptogenic cause. Patients with autoimmune and unknown/cryptogenic encephalitis shared similar clinical features. In unknown/cryptogenic encephalitis, the proportion of favorable outcomes (mRS 0-3) showed a different propensity at 3-6 months after discharge between patients receiving active immunotherapy and not receiving any immunotherapy, although it was not statistically significant (at admission 28.6% vs 20%, p = 0.603; at discharge 57.1% vs 60%, p = 0.570; at 3-6 months after discharge 90% vs 60%, p = 0.214 in patients treated with active immunotherapy or without immunotherapy, respectively). Extensive autoantibody screening should be carried out and empirical immunotherapy may be potentially helpful even in patients without antibodies, although longer term and multi-national studies may be necessary to make a stronger recommendation.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Neurology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.